These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29655767)

  • 41. Correction to: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guidelineon Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.
    Circulation; 2016 Sep; 134(10):e192-4. PubMed ID: 27601566
    [No Abstract]   [Full Text] [Related]  

  • 42. Dual antiplatelet therapy use by Canadian cardiac surgeons.
    Yanagawa B; Ruel M; Bonneau C; Lee MM; Chung J; Al Shouli S; Fagan A; Al Khalifa A; White CW; Yamashita MH; Currie ME; Teoh H; Mewhort HE; Verma S
    J Thorac Cardiovasc Surg; 2015 Dec; 150(6):1548-54.e3. PubMed ID: 26395051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease.
    Mauri L; Smith SC
    JAMA Cardiol; 2016 Sep; 1(6):733-4. PubMed ID: 27548911
    [No Abstract]   [Full Text] [Related]  

  • 44. Macrophage metabolism in atherosclerosis.
    Bories GFP; Leitinger N
    FEBS Lett; 2017 Oct; 591(19):3042-3060. PubMed ID: 28796886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting.
    Nocerino AG; Achenbach S; Taylor AJ
    Am J Cardiol; 2013 Nov; 112(10):1576-9. PubMed ID: 24035160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perioperative antiplatelet management in patients with coronary artery stenting.
    Tandar A; Velagapudi KN; Wilson BD; Boden WE
    Hosp Pract (1995); 2012 Apr; 40(2):118-30. PubMed ID: 22615086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [ESC/EACTS guidelines on myocardial revascularization : Amendments 2014].
    Nef H; Renker M; Hamm CW; ;
    Herz; 2014 Dec; 39(8):913-8. PubMed ID: 25406330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
    Eur Heart J; 2018 Apr; 39(13):1109. PubMed ID: 28369313
    [No Abstract]   [Full Text] [Related]  

  • 49. ESC/EACTS guidelines on myocardial revascularization post-SYNTAX.
    Mohr FW; Davierwala PM
    Eur J Cardiothorac Surg; 2014 Oct; 46(4):511-3. PubMed ID: 25193954
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ESC/EACTS myocardial revascularization guidelines 2014.
    Kolh P; Windecker S
    Eur Heart J; 2014 Dec; 35(46):3235-6. PubMed ID: 25482397
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
    Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
    Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The European Society of Cardiology (ESC) guidelines for percutaneous coronary interventions (PCI). Three case reports].
    Silber S; Richartz BM; Brilmayer M;
    Herz; 2006 Dec; 31(9):836-46, 848. PubMed ID: 17180646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implications of new ESC/EACTS guidelines on myocardial revascularization for patients with multivessel coronary artery disease.
    Ribichini F; Taggart D
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):663-6. PubMed ID: 21555430
    [No Abstract]   [Full Text] [Related]  

  • 56. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ;
    J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
    Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
    Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erratum to "Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy" [Can J Cardiol 40 (2024):160-181].
    Can J Cardiol; 2024 Jul; 40(7):1367. PubMed ID: 38740360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.